Imatinib treatment for idiopathic pulmonary fibrosis

Randomized placebo-controlled trial results

Craig E. Daniels, Joseph A. Lasky, Andrew H. Limper, Kathleen Mieras, Edith Gabor, Darrell R. Schroeder, Jeffrey Chapman, Steven Nathan, Moises Selman, Charles Alex, Augustine Lee, Leo Ginns, Joaode De Andrade, Imre Noth, Marilyn K Glassberg Csete, Janice Lieber, Lisa Lancaster, Paul Nobel, Stephen Pascoe, Jo Ann Duffy

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).

Original languageEnglish
Pages (from-to)604-610
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume181
Issue number6
DOIs
StatePublished - Mar 15 2010

Fingerprint

Idiopathic Pulmonary Fibrosis
Randomized Controlled Trials
Placebos
Therapeutics
Lung Diseases
Imatinib Mesylate
Clinical Trials
Carbon Monoxide
Protein-Tyrosine Kinases
Disease Progression
Research Personnel

Keywords

  • Idiopathic pulmonary fibrosis
  • Imatinib
  • Pulmonary function testing
  • Tryosine kinase inhibitor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., Schroeder, D. R., ... Duffy, J. A. (2010). Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. American Journal of Respiratory and Critical Care Medicine, 181(6), 604-610. https://doi.org/10.1164/rccm.200906-0964OC

Imatinib treatment for idiopathic pulmonary fibrosis : Randomized placebo-controlled trial results. / Daniels, Craig E.; Lasky, Joseph A.; Limper, Andrew H.; Mieras, Kathleen; Gabor, Edith; Schroeder, Darrell R.; Chapman, Jeffrey; Nathan, Steven; Selman, Moises; Alex, Charles; Lee, Augustine; Ginns, Leo; De Andrade, Joaode; Noth, Imre; Glassberg Csete, Marilyn K; Lieber, Janice; Lancaster, Lisa; Nobel, Paul; Pascoe, Stephen; Duffy, Jo Ann.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 6, 15.03.2010, p. 604-610.

Research output: Contribution to journalArticle

Daniels, CE, Lasky, JA, Limper, AH, Mieras, K, Gabor, E, Schroeder, DR, Chapman, J, Nathan, S, Selman, M, Alex, C, Lee, A, Ginns, L, De Andrade, J, Noth, I, Glassberg Csete, MK, Lieber, J, Lancaster, L, Nobel, P, Pascoe, S & Duffy, JA 2010, 'Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results', American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 604-610. https://doi.org/10.1164/rccm.200906-0964OC
Daniels, Craig E. ; Lasky, Joseph A. ; Limper, Andrew H. ; Mieras, Kathleen ; Gabor, Edith ; Schroeder, Darrell R. ; Chapman, Jeffrey ; Nathan, Steven ; Selman, Moises ; Alex, Charles ; Lee, Augustine ; Ginns, Leo ; De Andrade, Joaode ; Noth, Imre ; Glassberg Csete, Marilyn K ; Lieber, Janice ; Lancaster, Lisa ; Nobel, Paul ; Pascoe, Stephen ; Duffy, Jo Ann. / Imatinib treatment for idiopathic pulmonary fibrosis : Randomized placebo-controlled trial results. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 181, No. 6. pp. 604-610.
@article{f8c4ac5f5e3e404596db561d329e971c,
title = "Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results",
abstract = "Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10{\%} decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29{\%}) patients discontinued the study without reaching the primary endpoint (imatinib, 32{\%}; placebo, 27{\%}; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).",
keywords = "Idiopathic pulmonary fibrosis, Imatinib, Pulmonary function testing, Tryosine kinase inhibitor",
author = "Daniels, {Craig E.} and Lasky, {Joseph A.} and Limper, {Andrew H.} and Kathleen Mieras and Edith Gabor and Schroeder, {Darrell R.} and Jeffrey Chapman and Steven Nathan and Moises Selman and Charles Alex and Augustine Lee and Leo Ginns and {De Andrade}, Joaode and Imre Noth and {Glassberg Csete}, {Marilyn K} and Janice Lieber and Lisa Lancaster and Paul Nobel and Stephen Pascoe and Duffy, {Jo Ann}",
year = "2010",
month = "3",
day = "15",
doi = "10.1164/rccm.200906-0964OC",
language = "English",
volume = "181",
pages = "604--610",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Imatinib treatment for idiopathic pulmonary fibrosis

T2 - Randomized placebo-controlled trial results

AU - Daniels, Craig E.

AU - Lasky, Joseph A.

AU - Limper, Andrew H.

AU - Mieras, Kathleen

AU - Gabor, Edith

AU - Schroeder, Darrell R.

AU - Chapman, Jeffrey

AU - Nathan, Steven

AU - Selman, Moises

AU - Alex, Charles

AU - Lee, Augustine

AU - Ginns, Leo

AU - De Andrade, Joaode

AU - Noth, Imre

AU - Glassberg Csete, Marilyn K

AU - Lieber, Janice

AU - Lancaster, Lisa

AU - Nobel, Paul

AU - Pascoe, Stephen

AU - Duffy, Jo Ann

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).

AB - Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).

KW - Idiopathic pulmonary fibrosis

KW - Imatinib

KW - Pulmonary function testing

KW - Tryosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77749324295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749324295&partnerID=8YFLogxK

U2 - 10.1164/rccm.200906-0964OC

DO - 10.1164/rccm.200906-0964OC

M3 - Article

VL - 181

SP - 604

EP - 610

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -